Genetic risk factors for venous thrombosis

Molecular Genetics and Metabolism

Volumn 71, Issue 1-2, 2000, Pages 51-61

  Spek, C Arnold ^a   Reitsma, Pieter H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT PROTEIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; PROCOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR;

GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK FACTOR; SHORT SURVEY; THROMBOGENESIS; VEIN THROMBOSIS;

EID: 0033804596     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.2000.3051     Document Type: Article

References (96)

1. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
2. Mutation in blood coagulation factor V associated with resistance to activated protein C
3. World distribution of factor V Leiden
4. Polymorphisms of fibrinogen, factor VII and factor V genes: Comparison of allele frequencies in different ethnic groups
5. Coagulation factor V Leiden mutation may have a racial background
6. Arg 506 Gln factor V mutation is uncommon in eastern Asian populations
7. Activated protein C resistance
8. Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors - Correlation with absence of Arg506-Gln mutation of factor V gene
9. World distribution of factor V Leiden mutation
10. Low incidence of Arg 506 Gln mutation in the factor V gene among Amazonian Indians and Brazilian black population
11. A single genetic origin for a common Caucasian risk factor for venous thrombosis
12. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
13. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss - A possible evolutionary selection mechanism
14. Thrombomodulin deficiency results in enhanced host defense and increased survival in a murine model of peritonitis
15. Factor V Cambridge - A new mutation (Arg306Thr) associated with resistance to activated protein C
16. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese
17. Clinical significance of Arg306 mutations of factor V gene
18. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype
19. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden)
20. The factor V gene A4070G mutation and the risk of venous thrombosis
21. The factor V R2 allele: Risk of venous thromboembolism, factor V levels and resistance to activated protein C
22. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
23. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations
24. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
25. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - The Leiden Thrombophilia Study (LETS)
26. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals
27. The physiology and biochemistry of factor XIII
28. Association of a common polymorphism in the factor XIII gene with myocardial infarction
29. Factor XIII Val 34 Leu: A novel association with primary intracerebral hemorrhage
30. Association of a common polymorphism in the factor XIII gene with venous thrombosis
31. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis
32. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity
33. A common coding polymorphism in the FXIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity
34. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
35. Geographic distribution of the 20210 G to A prothrombin variant
36. A single genetic origin for the common prothrombotic G 20210A polymorphism in the prothrombin gene
37. A patient homozygous for a mutation in the prothrombin gene 3'-untranslated region associated with massive thrombosis
38. Homozygous prothrombin gene mutation and ischemic cerebrovascular disease: A case report
39. Homozygotes for prothrombin gene 20210 A allele in a thrombophilic family without clinical manifestations of venous thromboembolism
40. Structural biology of tissue factor, the initiator of thrombogenesis in vivo
41. Polymorphisms in the 5' regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: The ECTIM and PATHROS studies. Etude Cas-Temoins de l'Infarctus du Myocarde. Paris thrombosis case-control study
42. von Willebrand factor
43. von Willebrand factor in plasma: A novel risk factor for recurrent myocardial infarction and death
44. von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality
45. Characterization of the von Willebrand factor gene (VWF) in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin
46. Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: Identification of three novel single nucleotide polymorphisms in the vWF gene promoter
47. A single nucleotide polymorphism at nucleotide -1793 in the von Willebrand factor (VWF) regulatory region is associated with plasma VWF:Ag levels
48. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis
49. High levels of coagulation factor XI as a risk factor for venous thrombosis
50. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
51. Binding of thrombin to antithrombin III
52. Activation of human factor VII during clotting in vitro
53. Homozygous antithrombin deficiency: Report of two new cases (99 Leu to Phe) associated with arterial and venous thrombosis
54. Molecular heterogeneity of inherited antithrombin III deficiency
55. Antithrombin mutation database: 2nd (1997) update. For the plasma coagulation inhibitors subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis
56. The endothelial cell protein c receptor augments protein c activation by the thrombin-thrombomodulin complex
57. Structural and functional implications of the intron/exon organization of the human endothelial cell protein C/activated protein C receptor (EPCR) gene: Comparison with the structure of CD1/major histocompatibility complex alpha1 and alpha2 domains
58. A 23bp insertion in the endothelial protein C receptor (EPCR) gene in patients with myocardial infarction and deep vein thrombosis
59. Insight into the mechanism of action of heparin cofactor II
60. Molecular and cellular basis for type I heparin cofactor II deficiency (heparin cofactor II Awaji)
61. A heparin cofactor II mutation (HCII Rimini) combined with factor V Leiden or type I protein C deficiency in two unrelated thrombophilic subjects
62. Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis
63. Human plasma protein C: Isolation, characterization, and mechanism of activation by a-thrombin
64. Protein S and C4b-binding protein: Components involved in the regulation of the protein C anticoagulant system
65. Regulation of blood coagulation by the protein C system
66. The protein C anticoagulant pathway
67. Deficiency of protein C in congenital thrombotic disease
68. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant
69. Late-onset homozygous protein C deficiency
70. Protein C deficiency: A database of mutations, 1995 update. On behalf of the subcommittee on plasma coagulation inhibitors of the scientific and standardization committee of the ISTH
71. The mutational demography of protein C deficiency
72. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: Heterogeneity and founder effects
73. Familial protein S deficiency is associated with recurrent thrombosis
74. Neonatal purpura fulminans associated with homozygous protein S deficiency
75. Free protein S levels are elevated in familial C4b-binding protein deficiency
76. Two genes homologous with human protein S cDNA are located on chromosome 3
77. Protein S deficiency: A database of mutations. For the plasma coagulation inhibitors subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis
78. Protein C and protein S deficiencies
79. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460
80. Absence of linkage between type III protein S deficiency and the PROS1 and C4BP genes in families carrying the protein S Heerlen allele
81. The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type IIa) deficiency
82. Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: A possible mechanism of synergism between thrombophilic risk factors
83. A novel thrombomodulin gene mutation in a patient suffering from sagittal sinus thrombosis
84. Thrombomodulin gene variations and thromboembolic disease
85. Thrombomodulin with the Asp468Tyr mutation is expressed on the cell surface with normal cofactor activity for protein C activation
86. A frequent thrombomodulin amino acid dimorphism is not associated with thrombophilia
87. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction
88. Thrombomodulin gene mutations associated with myocardial infarction
89. Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction
90. Lipoprotein-association coagulation inhibitor
91. A first mutation in the human tissue factor pathway inhibitor gene encoding [P151L] TFPI
92. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: Impact of the V264M substitution on plasma levels of TFPI
93. No link between the TFPI V264M mutation and venous thromboembolic disease
94. The 536C → T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis
95. The TFPI 536C → T mutation is not associated with increased risk for venous or arterial thrombosis
96. Phenotypes of patients with 'simple' Mendelian disorders are complex traits: Thresholds, modifiers, and systems dynamics